The same was suggested by Schaaij-Visser and colleagues when revealing that the low expression of KRT4 in samples from patients with head and neck squamous cell carcinomas (HNSCC), including OSCC samples, may serve as a screening biomarker for local recurrence risk and allow selection for adjuvant treatment or tertiary prevention studies28. This evidence concerns the gene KRT4 and head and neck squamous cell carcinoma.